ASP Isotopes Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2023; filed November 14, 2023. ASP Isotopes is a pre-commercial advanced materials company developing isotope-enrichment technologies, including the Aerodynamic Separation Process for C-14, Mo-100 and Si-28, and quantum enrichment for additional isotopes. The company has no approved products and has not generated isotope sales revenue.
Business Context and Reporting Period
- The company commissioned its first C-14 enrichment plant in Pretoria, South Africa, and expected completion and commissioning of a second multi-isotope plant during the first half of 2024.
- Property and equipment was primarily construction in progress related to the South African facilities.
- In June 2023, the company entered into a supply agreement for Mo-100 and molybdenum-98 beginning in 2024 and received a $882,000 customer advance, recorded as deferred revenue.
- On April 4, 2023, the company acquired certain intellectual property and other assets from Klydon in settlement of obligations under a turnkey plant-construction arrangement.
Financial Results and Key Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $239,199 vs. $745,461 | $699,413 vs. $1,191,901 |
| General and administrative expense | $3,707,311 vs. $1,208,319 | $11,319,465 vs. $2,448,091 |
| Total operating expenses | $3,946,510 vs. $1,953,780 | $12,018,878 vs. $3,639,992 |
| Net loss | $4,222,483 vs. $1,956,230 | $12,123,907 vs. $3,640,988 |
| Net loss per share | $0.14 vs. $0.06 | $0.40 vs. $0.13 |
| Cash used in operating activities | Not separately presented | $3,355,171 vs. $2,077,859 |
| Cash used in investing activities | Not separately presented | $1,190,157 vs. $3,570,632 |
| Cash provided by financing activities | Not separately presented | $4,493,610 vs. $2,850,549 |
- Stock-based compensation was $2,071,790 in the third quarter and $6,590,576 for the first nine months, substantially increasing reported operating expenses while reducing the cash impact of the net loss.
- Cash was $2,286,805 at September 30, 2023, compared with $2,389,140 at December 31, 2022.
- Total assets were $11,871,392, including $8,346,920 of property and equipment, primarily construction in progress.
- Total liabilities were $3,231,905, including $882,000 of deferred revenue, $679,267 of operating lease liabilities and $33,854 of notes payable. The filing states there was no bank debt outstanding.
- Accumulated deficit was $19,676,973 at September 30, 2023.
Material Changes Versus Prior Comparable Period
- Third-quarter net loss increased by $2,266,253, or approximately 116%, primarily because general and administrative expense increased by $2,498,992. The increase included higher stock-based compensation, professional and legal fees, and corporate costs.
- Nine-month net loss increased by $8,482,919, or approximately 233%, primarily because general and administrative expense increased by $8,871,374.
- Research and development expense declined by $506,262 for the quarter and $492,488 for the nine-month period, mainly because prior-period license fees were not repeated.
- Nine-month operating cash use increased by $1,277,312, while investing cash use declined by $2,380,475 because construction spending was lower than in the prior period.
- The company raised $5.0 million of gross proceeds in March 2023 through an equity and warrant offering, generating $4,493,610 of net financing cash flow after issuance costs.
- Common shares outstanding increased from 35,907,127 at December 31, 2022 to 38,348,184 at September 30, 2023. Potential dilution included 2,814,333 options, 3,386,076 warrants and 6,415,874 unvested restricted shares.
Liquidity, Outlook, Risks and Unusual Items
- Management stated that cash at September 30, 2023, together with $9,129,461 received in October 2023 from issuing 9,952,510 common shares, is not expected to fund operating expenses and capital requirements for more than 12 months from the financial statement issuance date.
- The filing includes a going-concern disclosure and states that substantial additional funding is necessary. Additional equity, debt or collaborative financing may not be available on acceptable terms or at all.
- In October 2023, the company issued 9,952,510 common shares for aggregate cash consideration of $9,129,461. This financing materially increased liquidity but also created significant shareholder dilution.
- The company expects commercial isotope revenues, if any, to begin no earlier than 2024. It has not demonstrated commercial-scale production, obtained all potentially required regulatory approvals, or established commercial sales capabilities.
- The initial Mo-100 plant construction commitment was approximately $6.8 million for capacity of at least 5 kilograms, with a potential additional $6.0 million for expanded capacity. Approximately $7.233 million had been paid under the contract and capitalized as construction in progress.
- On October 30, 2023, the company agreed to purchase 51% of PET Labs for $2.0 million, with $500,000 paid in November 2023 and $1.5 million payable after October 27, 2024. It also holds an option to acquire the remaining 49% for $2.2 million through January 31, 2027.
- The company’s disclosure controls and procedures were ineffective as of September 30, 2023 because of a previously identified material weakness in internal control over financial reporting. Management plans to add accounting, finance and information-technology resources or consultants.
- Key risks include construction and commissioning failures, regulatory and nuclear non-proliferation requirements, dependence on third-party suppliers and contractors, foreign-exchange and South African operating risks, limited intellectual-property protection, market acceptance, future financing needs and potential dilution.
- The company received a Nasdaq minimum-bid-price deficiency notice in May 2023 but reported regaining compliance in August 2023.
- A previously asserted intellectual-property dispute involving NMS and Radfarma was resolved in November 2023 through a mutual release without payment or license of rights by any party.
Most Important Facts for Investors to Verify
- Whether the October 2023 equity financing and subsequent cash balance provide sufficient runway, given management’s explicit going-concern uncertainty.
- The actual completion, commissioning, regulatory status and production performance of the South African C-14 and multi-isotope facilities.
- Whether the Mo-100 supply agreement will result in recognized revenue beginning in 2024, including fulfillment obligations associated with the $882,000 advance.
- Remaining construction commitments, funding requirements and the status of the Klydon turnkey-contract settlement and acquired technology.
- The financial impact, accounting treatment and funding obligations associated with the PET Labs acquisition.
- Progress in remediating the material weakness in internal controls and any future restatements or reporting delays.
- Regulatory approvals, export controls, intellectual-property ownership and freedom-to-operate for ASP and quantum-enrichment technologies.
- Potential dilution from outstanding warrants, options, restricted shares, equity compensation and additional financing.